UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO

RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2018

Commission File No. 001-38691

AURORA CANNABIS INC.

 


(Translation of registrant's name into English)

500 - 10355 Jasper Avenue
Edmonton, Alberta, T5J 1Y6, Canada

 


(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☐          Form 40-F  ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)  ☐

 

 

 

 

 
 

SUBMITTED HEREWITH

 

Exhibits Description 
99.1   Form 51-102F3 - Material Change Report dated December 7, 2018
     

 

 
 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AURORA CANNABIS INC.

/s/ Glen Ibbott

 


Glen Ibbott
Chief Financial Officer

Date: December 7, 2018

Exhibit 99.1

 

FORM 51-102F3

MATERIAL CHANGE REPORT

 

Item 1. Name and Address of Company
   
  Aurora Cannabis Inc. (“ Aurora ” or the “ Company ”)
  500 - 10355 Jasper Avenue
  Edmonton, Alberta
  T5J 1Y6
   
Item 2. Date of Material Change
   
  November 14, 2018.
   
Item 3. News Release
   
  A news release with respect to the material change referred to in this report was issued in Canada through the facilities of Canada Newswire and filed on SEDAR on November 14, 2018.
   
Item 4. Summary of Material Change
   
  On November 14, 2018, the Company announced the appointment of Dr. Jonathan Page as Chief Science Officer.
   
Item 5. Full Description of Material Change
  5.1           Full Description of Material Change

 

On November 14, 2018, the Company announced inter alia , as follows:

 

The appointment of Dr. Jonathan Page, PhD as the Company’s Chief Science Officer .

 

In this new role, Dr. Page will oversee all science-related projects at the Company. The Aurora science team develops innovative products for the medical, wellness and adult consumer markets and focuses on delivering industry-leading cultivation results in terms of yields, consistency, quality and efficiency.

 

Dr. Page is a globally renowned cannabis scientist, with 37 peer-reviewed publications, who was the co-lead of the Canadian team of scientists who first sequenced the cannabis genome. His work also helped discover the biochemical pathways leading to the major cannabinoids. Prior to his appointment, Dr. Page served as CEO of recently acquired Anandia Labs, the world-leading cannabis-focused science company he co-founded.

 

Aurora has ingrained scientific methods throughout the Company, which it uses to drive efficiencies, medical and plant discovery and product innovation. That approach will only increase with Dr. Page’s appointment. With more than 40 PhD- and MSc-level researchers, Aurora has cutting-edge research programs designed to develop competitive advantages.

 

An entrepreneurial scientist, Dr. Page co-founded Anandia Labs, which specializes in cannabis genetics, metabolite profiling, plant breeding, disease characterization, and cultivar certification, as well as providing third party independent testing services to producers and patient-cultivators. Dr. Page is an adjunct professor in the Botany Department at the University of British Columbia (UBC) who received his PhD from UBC, undertook postdoctoral training in Germany, and for a decade directed a lab at the National Research Council.

 

 

 

Dr. Page is also an accomplished inventor with eight issued patents or patent applications, and a frequent lecturer on cannabis science at international conferences.

 

Anandia will continue to operate independently of Aurora. Dr. John Coleman, PhD will be taking over as President at Anandia.

 

5.2

Disclosure for Restructuring Transactions

   
  Not applicable.
   
Item 6. Reliance on Subsection 7.1(2) of National Instrument 51-102
   
  Not applicable.
   
Item 7. Omitted Information
   
  Not applicable.
   
Item 8. Executive Officer
   
The following senior officer of the Company is knowledgeable about the material change and this Material Change Report and may be contacted:
   
Terry Booth, Chief Executive Officer
(604) 362-5207
 
Item 9. Date of Report
   
  December 7, 2018